COMMUNIQUÉS West-GlobeNewswire

MBX Biosciences to Host Virtual Investor Event to Discuss Once-Weekly Canvuparatide Presentations at ENDO 2026
01/06/2026
CARMEL, Ind., June 01, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide [...]
Nasus Pharma to Host Virtual KOL Event on June 10, 2026 to Discuss NS002 for the Treatment of Anaphylaxis
01/06/2026
TEL AVIV, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products [...]
Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors
01/06/2026
Presentation highlights early clinical activity from ACESOT-1051, including partial responses and stable disease in patients across multiple tumor types Manageable tolerability confirmed across cohorts Patient expansion [...]
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/06/2026
BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it [...]
Spectral AI Announces Voting Results of Annual Meeting of Stockholders
01/06/2026
Provides Update and Outlook Following Receipt of FDA De Novo Clearance for DeepView® System for Burn Indication DALLAS, June 01, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company [...]
Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026
01/06/2026
SOUTH SAN FRANCISCO, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell [...]
ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York
01/06/2026
SOUTH SAN FRANCISCO, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat [...]
MAIA Biotechnology Presents Trial in Progress Poster for Pivotal Phase 3 Clinical Trial of Novel Telomere Targeting Agent at 2026 Annual Meeting of American Society of Clinical Oncology
01/06/2026
CHICAGO, June 01, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, [...]
Beyond Air Receives Nasdaq Hearing Panel Decision Granting Continued Listing
01/06/2026
GARDEN CITY, N.Y., June 01, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve [...]
Aplagon Announces Review Publication on APAC, a First-in-Class Dual-Action Antithrombotic to Treat Unmet Clinical Needs in Thromboinflammatory Diseases
01/06/2026
HELSINKI, June 01, 2026 (GLOBE NEWSWIRE) -- Aplagon , a clinical-stage biotech developing first-in-class therapies for thromboinflammatory diseases, today announced the comprehensive publication of an invited review [...]
Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor Cevidoplenib
01/06/2026
Agios obtains exclusive global rights to novel, late-stage, next-generation, oral SYK inhibitor Agreement diversifies Agios’ rare hematology portfolio with expansion into immune thrombocytopenia, unlocking up to $1 [...]
ITM Announces Phase 3 COMPETE Data Supporting Single-Timepoint Dosimetry for n.c.a. ¹⁷⁷Lu-edotreotide (ITM-11) in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) at SNMMI 2026
01/06/2026
Analysis from the Phase 3 COMPETE trial suggests population-based modeling may enable accurate individualized dosimetry with substantially fewer imaging requirements Los Angeles, California, June 1, 2026 — ITM Isotope [...]
Alvotech and Islandsbanki renew Market Making Agreement for ALVO Shares Trading on Nasdaq Iceland
01/06/2026
REYKJAVIK, ICELAND (June 1, 2026) — Alvotech (Nasdaq: ALVO) and Islandsbanki have renewed and amended their existing market making agreement. According to the agreement, Islandsbanki places bids and offers for ALVO [...]
Avacta presents updated clinical data showing encouraging early efficacy signals for AVA6000 in salivary gland cancers at ASCO 2026
01/06/2026
Multiple confirmed partial and minor responses observed in patients with SGC Continuing very good safety profile, with removal of the lifetime maximum doxorubicin limit based on highly favorable cardiac safety LONDON [...]
Intravacc and Primrose Bio Renew Partnership to Enhance Conjugate Vaccine Development
01/06/2026
The companies will leverage their combined experience in the development of conjugate vaccines for their clients Primrose Bio will supply its industry-leading carrier protein, PeliCRM197®, for vaccine development [...]
Curium Announces a Strategic Investment of Over €32 million in Saclay, France
01/06/2026
Curium’s strategic investment of over €32 million will establish a European production line for 177 Lu-PSMA-I&T, a therapeutic agent for patients with metastatic castration-resistant prostate cancer This investment [...]
UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus
01/06/2026
Publication adds to previously reported findings from Phase 3 PHOENYCS GO study, demonstrating statistically significant improvement in disease activity at Week 48 with dapirolizumab pegol plus standard of care versus [...]
Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseases
01/06/2026
New Cosentyx ® (secukinumab) data from REPLENISH, largest ever global Phase III trial in polymyalgia rheumatica, to be highlighted in oral session New ianalumab interim results from Sjögren’s Phase III extension study [...]
Idorsia reports new positive results with its breakthrough C. difficile vaccine – underscoring the unique potential of its glycan technology
01/06/2026
High-dose cohort confirms the favorable safety profile and the dose-dependent immune response against Clostridioides difficile bacteria and spores Allschwil, Switzerland – June 1, 2026 Idorsia Ltd (SIX: IDIA) today [...]

Pages